These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 1692497)

  • 1. Prostate tumour markers as an aid in the staging of prostatic cancer.
    Haapiainen RK; Permi EJ; Rannikko SA; Voutilainen PE; Liewendahl K; Stenman UH; Alfthan OS
    Br J Urol; 1990 Mar; 65(3):264-7. PubMed ID: 1692497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate tumour markers and differentiation grade in prostatic cancer.
    Haapiainen RK; Permi EJ; Rannikko SA; Voutilainen PE; Alfthan OS
    Br J Urol; 1990 Dec; 66(6):635-8. PubMed ID: 1702339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumour markers in prostatic carcinoma. A comparison of prostate-specific antigen with acid phosphatase.
    Ferro MA; Barnes I; Roberts JB; Smith PJ
    Br J Urol; 1987 Jul; 60(1):69-73. PubMed ID: 2441790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of pelvic lymph node metastases by a prostate-specific antigen and prostatic acid phosphatase in clinical T3/T4M0 prostatic cancer.
    Waehre H; Wanderaas EH; Paus E; Fosså SD
    Eur Urol; 1992; 22(1):33-8. PubMed ID: 1385143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contribution of bone scintigraphy, prostatic acid phosphatase and prostate-specific antigen to the monitoring of prostatic cancer.
    Hetherington JW; Siddall JK; Cooper EH
    Eur Urol; 1988; 14(1):1-5. PubMed ID: 2449352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative study of the clinical usefulness of prostate specific antigen and prostatic acid phosphatase in prostatic disease.
    Buamah PK; Johnson P; Skillen AW
    Br J Urol; 1988 Dec; 62(6):581-3. PubMed ID: 2464396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical usefulness of prostate-specific antigen and prostatic acid phosphatase in patients with prostatic cancer.
    Filella X; Molina R; Jo J; Umbert B; Bedini JL; Ballesta AM
    Tumour Biol; 1990; 11(6):289-94. PubMed ID: 1700860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Role of the markers PAP-PSA in the diagnosis of cancer of the prostate].
    Petrone U; Gaspari G; Marascia G; Magnocavallo N; Petrone D; Tucci C
    Minerva Urol Nefrol; 1990; 42(2):73-5. PubMed ID: 1697431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of prostate-specific antigen in untreated prostatic carcinoma.
    Oosterom R; Bogdanowicz J; Schröder FH
    Eur Urol; 1989; 16(4):253-7. PubMed ID: 2475344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spontaneous circadian fluctuations of prostate specific antigen and prostatic acid phosphatase serum activities in patients with prostatic cancer.
    Mannini D; Maver P; Aiello E; Corrado G; Vecchi F; Bellanova B; Marengo M
    Urol Res; 1988; 16(1):9-12. PubMed ID: 2449758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative experimental study of the serum prostate specific antigen and prostatic acid phosphatase in serially transplantable human prostatic carcinoma lines in nude mice.
    Csapo Z; Brand K; Walther R; Fokas K
    J Urol; 1988 Nov; 140(5):1032-8. PubMed ID: 2459419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunologically measured serum markers and their role in the management of prostate cancer.
    Powell P; Neal D; Gibb I; Wilson L; Hall R
    Eur Urol; 1988; 15(1-2):48-53. PubMed ID: 2463921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum TPS, PSA, and PAP values in relapsing stage D2 adenocarcinoma of the prostate.
    Kraljić I; Kovacić K; Tarle M
    Urol Res; 1994; 22(5):329-32. PubMed ID: 7533445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum osteocalcin measurements in prostate carcinoma patients with skeletal deposits shown by bone scintigram: comparison with serum PSA/PAP measurements.
    Shih WJ; Wierzbinski B; Collins J; Magoun S; Chen IW; Ryo UY
    J Nucl Med; 1990 Sep; 31(9):1486-9. PubMed ID: 1697617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate specific antigen--a screening test for prostatic cancer?
    Powell CS; Fielding AM; Rosser K; Ames AC; Vaughton KC
    Br J Urol; 1989 Nov; 64(5):504-6. PubMed ID: 2482112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-comparison of PSA and PAP values in a wide spectrum of prostate cancer conditions.
    Tarle M
    Anticancer Res; 1988; 8(4):569-72. PubMed ID: 2460018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum prostatic acid phosphatase, gamma-seminoprotein and prostatic specific antigen in hemodialysis patients.
    Sasagawa I; Nakada T; Hashimoto T; Ishigooka M; Kubota Y; Hirano K; Hirano J; Suzuki Y
    Urol Int; 1992; 48(2):181-3. PubMed ID: 1374977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between prostate-specific antigen, clinical stage, and degree of bone metastasis in patients with prostate cancer: comparison with prostatic acid phosphatase and alkaline phosphatase.
    Akimoto S; Furuya Y; Akakura K; Shimazaki J; Ito H
    Int J Urol; 1997 Nov; 4(6):572-5. PubMed ID: 9477186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate-specific antigen in management of prostatic carcinoma.
    Brawer MK; Lange PH
    Urology; 1989 May; 33(5 Suppl):11-6. PubMed ID: 2469244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An evaluation of the immunochemical measurement of prostatic acid phosphatase and prostatic specific antigen in carcinoma of the prostate.
    Siddall JK; Cooper EH; Newling DW; Robinson MR; Whelan P
    Eur Urol; 1986; 12(2):123-30. PubMed ID: 2420600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.